Personalized drug screening for recurrent glioblastoma brain tumors
Tests tumor stem cell cultures to guide drug choice in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM)
Key facts
- Where
- Oslo, NorwaySee the site
- Phase
- Phase 1
Where in Norway
- Oslo University Hospital HFOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital HF
- Trial code
- NCT05043701EU 2023-510214-11-00
- Record updated
- 23 February 2026
- Original description
Establishment and feasability evaluation of high-throuhput drug screens of personalized tumor stem cell cultures. Success of generating an individualized treatment selection based on drug screening.Read full original descriptionShow less
Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM)
Establishment and feasability evaluation of high-throuhput drug screens of personalized tumor stem cell cultures. Success of generating an individualized treatment selection based on drug screening.
Inclusion: Histologically verified glioblastoma; Must be ambulatory with an ECOG performance status 0-1; Must be 18 to 70 years of age; Adequate bone marrow, liver and heart function; Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
Exclusion: Patients taking part in other clinical trials which could make incusion or follow-up difficult; Any reason why, in the opinion of the investigator, the patient should not participate.